Daiichi Sankyo Co Ltd (4568.T)
4568.T on Tokyo Stock Exchange
3,758JPY
20 Apr 2018
3,758JPY
20 Apr 2018
Change (% chg)
¥34 (+0.91%)
¥34 (+0.91%)
Prev Close
¥3,724
¥3,724
Open
¥3,723
¥3,723
Day's High
¥3,804
¥3,804
Day's Low
¥3,720
¥3,720
Volume
1,253,900
1,253,900
Avg. Vol
2,391,456
2,391,456
52-wk High
¥4,241
¥4,241
52-wk Low
¥2,284
¥2,284
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Joji Nakayama |
67 | 2017 | Chairman of the Board, Chief Executive Officer, Representative Director |
Sunao Manabe |
62 | 2017 | Executive President, President, Chief Operating Officer, Representative Director |
Kazunori Hirokawa |
66 | 2017 | Executive Vice President, Vice President, Chief Financial Officer, Representative Director |
Kentaro Takamura |
2017 | Executive Officer, Director of Finance & Accounting in Main Business Strategy Unit | |
Satoru Kimura |
2016 | Senior Managing Executive Officer, Chief Director of Medicine Sales |
- BRIEF-Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative
- BRIEF-Daiichi Sankyo completes share repurchase
- BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case
- BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201
- BRIEF-Medrx signs joint development contract with DAIICHI SANKYO